Tragara reports lung cancer drug results
June 7th, 2011
by Keith Darce
Lung cancer patients under the age of 65 who received Tragara Pharmaceuticals’ lead experimental drug, Capoxigem, survived three times longer than those taking a placebo, according to results from a Phase 2 trial of the San Diego company’s therapy.
The drug and placebo were given in combination with erlotinib, a chemotherapy drug given to patients with advanced forms of the most common form of non-small cell lung cancer, the most common form of the disease.
At 10:51 am on June 8th, 2011 Mesothelioma Resource Site said:
I’m just wondering if more information will be posted as the research develops. I work with http://www.Asbestos.net/ and many of my clients who suffer from lung cancer due to asbestos exposure would take great interest in new treatment possibilities. Regards
At 5:01 pm on June 10th, 2011 sam said:
We’re constantly updating the research as it comes out. Thank you for your message! -Nicolle